DataMEDS AI, Inc. (MEDS) Financial Statements
DataMEDS AI, Inc. (MEDS) reported trailing twelve-month revenue of $8.0M (down 78.2% year on year) and net income of -$88.3M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$14.7M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
MEDSDataMEDS AI, Inc.Follow MEDS — free
—
Price chart with a free account
- Market cap
- 6.8M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 18 Nov, in 25 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|
| Revenue | 18.1 | 23.3 | 8.0 | |
| Gross profit | 1.8 | -6.4 | -7.3 | |
| Operating income | -6.1 | -93.7 | -70.3 | |
| Pre-tax income | -6.9 | -101.3 | -88.3 | |
| Net income | -6.9 | -101.3 | -88.3 | |
| Diluted EPS ($) | -0.15 | -1.43 | -34.06 | |
| Diluted shares (mn) | 47.3 | 71.0 | — |
USD millions · SEC XBRL
DataMEDS AI, Inc. — questions
- What is DataMEDS AI, Inc.'s revenue?
- $8.0M over the twelve months to 2026-06-30, down 78.2% year on year, from its 10-Q and 10-K filings.
- What is DataMEDS AI, Inc.'s net income?
- -$88.3M over the twelve months to 2026-06-30.
- What is DataMEDS AI, Inc.'s free cash flow?
- -$14.7M over the twelve months to 2026-06-30.
- What are DataMEDS AI, Inc.'s diluted earnings per share?
- $-34.06 over the twelve months to 2026-06-30.
Every figure on this page comes from DataMEDS AI, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.